logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Drugs

Results

Drugs

July 2021

Afamitresgene autoleucel for advanced synovial sarcoma or myxoid/round cell liposarcoma

Afamitresgene autoleucel is in clinical development for the treatment of advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) in patients who have previously had chemotherapy. Both synovial sarcoma and MRCLS are two different types of soft tissue sarcomas (STS), a rare form of cancer that develops in the tissues that connect, support and surround other …

Drugs

July 2021

Pembrolizumab in combination with lenvatinib, platinum chemotherapy, and pemetrexed for non-small cell lung cancer

The combination of pembrolizumab, lenvatinib, platinum chemotherapy, and pemetrexed is in clinical development for the treatment of metastatic non-squamous non-small cell lung cancer (NSCLC). NSCLC makes up the majority of lung cancers in the UK and at the metastatic stage (stage IV), the disease has already spread from the lungs to other sites. Most patients …

Drugs

July 2021

Dronabinol for muscle spasticity caused by multiple sclerosis

Dronabinol is in clinical development for the treatment of spasticity caused by multiple sclerosis (MS). MS is a long-term condition that affects the brain and spinal cord, causing a range of symptoms including spasticity. Spasticity is when the muscles become stiff and resistant to movement, which can be extremely painful. There are currently limited treatment …

Drugs

July 2021

Leronlimab in addition to antiretroviral therapy for treatment experienced adult HIV-1 patients

Leronablim is in clinical development to treat experienced adult HIV-1 patients infected with C-C chemokine receptor type 5 (CCR5)-tropic virus. Antiretroviral medicines are used to treat HIV. However, poor adherence and the subsequent development of drug resistance is one reason why HIV treatment can fail and therefore requires more treatment options. Leronlimab is an antibody …

Drugs

July 2021

Nivolumab in combination with ipilimumab for gastric or gastroesophageal junction cancer – first line

Nivolumab in combination with ipilimumab is under development for the treatment of advanced gastric or gastroesophageal junction cancer. Gastric cancer is a malignant tumour originating in the cells of the stomach. Advanced gastric cancer begins in the stomach and spread into the tissues around the stomach, either as locally advanced disease, or it can metastasise …

Drugs

July 2021

Risankiziumab for moderate to severe crohn’s disease

Risankizumab is in development as a treatment option for moderate to severe Crohn’s disease (CD). CD is a type of inflammatory bowel disease which can affect any part of the digestive system. CD causes inflammation and ulceration, which affects food digestion, nutrient absorption, and waste elimination. Symptoms include abdominal pain, diarrhoea, weight loss and fatigue. …

Drugs

July 2021

Daprodustat for anaemia associated with chronic kidney disease

Daprodustat is in clinical development for people with anaemia associated with chronic kidney disease (CKD). Anaemia is the term used to describe a decrease in normal levels of red blood cells and is assessed by the level of haemoglobin, the protein that transports oxygen throughout the body. Anaemia commonly occurs in patients with kidney dysfunction …

Drugs

July 2021

Betula verrucosa for tree pollen allergy-induced moderate to severe rhinoconjunctivitis

Betula verrucosa is in clinical development for the treatment of adults with confirmed tree pollen allergy-induced moderate to severe rhinoconjunctivitis. Allergic rhinoconjunctivitis is an allergic disorder of the nose and resulting in a chronic, mostly eosinophilic, inflammation of the nasal mucosa and conjunctiva. When the conjunctiva is also involved, the term rhinoconjunctivitis is more accurate. …

Drugs

June 2021

Duvelisib for Relapsed or Refractory Chronic Lymphocytic Leukaemia

Duvelisib is an anti-cancer drug in clinical development for adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies. CLL is a type of cancer in which too many white blood cells are produced. As these cells develop abnormally, they are unable to function and fight infection and reduce …

Drugs

June 2021

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma

Glofitamab is in clinical development for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL) and primary mediastinal large B-cell lymphoma (PMBCL). HGBCL and PMBCL are subtypes of DLBCL which is a type of blood cancer that develops when white blood cells, called lymphocytes, grow out of …

Get Alerts